EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties

Appl Health Econ Health Policy. 2018 Aug;16(4):429-432. doi: 10.1007/s40258-018-0393-7.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Drug Approval* / methods
  • Drug Approval* / organization & administration
  • Drug Approval* / statistics & numerical data
  • European Union / organization & administration
  • Humans
  • Uncertainty
  • United Kingdom

Substances

  • Antineoplastic Agents